Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension
Retrieved on:
Wednesday, May 19, 2021
The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-daily treatment consisting of firibastat associated with enalapril and hydrochlorothiazide is significantly greater than that induced by firibastat alone or by bitherapy enalapril/hydrochlorothiazide.
Key Points:
- The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-daily treatment consisting of firibastat associated with enalapril and hydrochlorothiazide is significantly greater than that induced by firibastat alone or by bitherapy enalapril/hydrochlorothiazide.
- \xe2\x80\x9cThese data follow those already obtained from studies of firibastat as monotherapy and further reinforce our strategy of using firibastat to improve blood pressure control in hypertensive patients who are difficult to treat or resistant.\xe2\x80\x9d\nQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI).
- Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.
- The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Coll\xc3\xa8ge de France (French National Institute of Health and Medical Research (INSERM) / the Scientific Centre for National Research (CNRS)).